Results 51 to 60 of about 63,242,370 (271)

Impact of Radiation Therapy on Physical and Psychosocial Health of Adolescents and Young Adults: A Joint Report From the Children's Oncology Group AYA and Radiation Oncology Committees

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Rates of cancer among adolescents and young adults (AYA), age 15–39 years, are increasing. Consequently, radiation oncologists are treating more AYAs who have diagnoses spanning both pediatric and adult practices. Compared to pediatric and older adult patients, AYAs face a unique set of challenges.
Hesham Elhalawani   +7 more
wiley   +1 more source

IL-27 regulates IL-18 binding protein in skin resident cells [PDF]

open access: yes, 2012
IL-18 is an important mediator involved in chronic inflammatory conditions such as cutaneous lupus erythematosus, psoriasis and chronic eczema. An imbalance between IL-18 and its endogenous antagonist IL-18 binding protein (BP) may account for increased ...
Wittmann, M   +23 more
core   +2 more sources

Social Functioning Within the First Years After Pediatric Brain Tumor Diagnosis and the Relationship With Family Psychosocial Risk

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Survivors of pediatric brain tumors (PBTs) can experience long‐term social difficulties, impacting quality of life. Beyond medical and environmental factors, family psychosocial risk may play a role in social outcomes by shaping the caregiving environment and may provide intervention options.
Renske H. Houben   +4 more
wiley   +1 more source

Pro-inflammatory signaling by IL-10 and IL-22: bad habit stirred up by interferons? [PDF]

open access: yes, 2013
Interleukin (IL)-10 and IL-22 are key members of the IL-10 cytokine family that share characteristic properties such as defined structural features, usage of IL-10R2 as one receptor chain, and activation of signal transducer and activator of ...
Heiko Mühl, Heiko eMühl, Mühl, Heiko
core   +1 more source

Determination of the functional biology of IL‐25

open access: yesThe FASEB Journal, 2008
Interleukin (IL)‐25 (IL‐17E) is a recently described member of the IL‐17 cytokine family. Recent studies have demonstrated key functions of IL‐25 in T H 2 cytokine‐mediated host protective immunity and in the inhibition of IL‐17‐mediated inflammation.
Steven A. Saenz   +4 more
openaire   +1 more source

Cytokines (interleukin-9, IL-17, IL-22, IL-25 and IL-33) and asthma

open access: yesAdvanced Biomedical Research, 2014
Asthma is a reversible airway obstruction that is characterized by constriction of airway smooth muscle, hyper secretion of mucus, edema and airway hyper responsiveness (AHR), mucus secretion and thickening of the basement membrane underlying the airway ...
Rahim Farahani   +4 more
doaj   +1 more source

Retrospective Analysis of Donor Lymphocyte Infusions in Pediatric Patients With Mixed Chimerism After Hematopoietic Stem Cell Transplantation

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Allogeneic hematopoietic stem cell transplantation (alloHSCT) is an essential therapy for several malignant and nonmalignant diseases, but relapse and graft loss remain the principal threats to its success. Routine monitoring of chimerism and minimal residual disease (MRD) enables early detection of imminent recurrence and guides ...
Carmen Junk   +10 more
wiley   +1 more source

IL-25 enhances production of IgMFt.

open access: yes, 2021
(A) IL-25 was measured in BALF or thoracic cavity lavage 18 hrs post immunization or infection in WT B6 mice (n = 3). (B, C) WT B6 mice were treated with recombinant IL-25 and immunized i.n. with LPSFt. Seven days p.i.
Fabio Re (189981)   +4 more
core   +1 more source

Pediatric Idiopathic Multicentric Castleman Disease Is Often Severe But Responsive to Siltuximab

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Idiopathic multicentric Castleman disease (iMCD) is a potentially fatal immunologic disorder marked by widespread lymphadenopathy and inflammation. Siltuximab, an interleukin‐6 (IL‐6) inhibitor, is the only FDA‐approved treatment for adult patients with iMCD.
Bridget Austin   +17 more
wiley   +1 more source

Serum levels of interleukin-17, -18, -22, and -25 in patients with bullous pemphigoid before and after treatment

open access: yesFrontiers in Medicine
ObjectiveThis study aimed to explore the relationship between serum levels of interleukin-17 (IL-17), interleukin-18 (IL-18), interleukin-22 (IL-22), interleukin-25 (IL-25), anti-BP180 antibodies, anti-BP230 antibodies, and immunoglobulin E (IgE) and the
Xinyi Hong   +23 more
doaj   +1 more source

Home - About - Disclaimer - Privacy